Aeluma, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2024; filed May 10, 2024. The filing describes a research-and-development-stage company developing compound-semiconductor optoelectronic devices for sensing and communications. Its unaudited statements are consolidated with its subsidiary.
Financial results and liquidity
| Metric | Three months ended March 31, 2024 | Nine months ended March 31, 2024 |
|---|---|---|
| Revenue | $343,894 | $639,286 |
| Cost of revenue | $233,585 | $385,491 |
| Gross profit / margin | $110,309 / approximately 32.1% | $253,795 / approximately 39.7% |
| Operating expenses, including cost of revenue | $1,306,662 | $4,213,564 |
| Net loss | $(962,651) | $(3,573,480) |
| Basic and diluted loss per share | $(0.08) | $(0.29) |
Nine-month revenue consisted of $606,886 from government contracts and $32,400 from product sampling sales. Cash and cash equivalents were $1,874,565 at March 31, 2024, down from $5,071,690 at June 30, 2023. Working capital was $1,495,903, compared with $4,576,807 at fiscal year-end. Nine-month cash used in operations was $2,876,190; cash used in investing was $316,934, primarily for equipment. No conventional borrowings are reported; liabilities include operating lease obligations of $1,101,076, of which $126,420 is current.
Changes versus comparable periods
- Revenue was zero in the prior-year quarter and nine-month period, so the current-period revenue reflects initial commercial and government-contract activity.
- Quarterly net loss narrowed to $962,651 from $1,460,801. For the nine months, net loss narrowed to $3,573,480 from $4,071,391.
- Nine-month operating expenses fell $76,513 year over year, mainly from lower consulting expenses, partly offset by higher salaries and stock compensation.
- Prior-year nine-month other income of $218,686 fell to $798, principally because the facility sublease ended in March 2023.
- Cash declined by $3,197,125 during the nine months, versus a $1,116,533 increase in the prior-year period, when private-placement proceeds provided $4,071,145 of net financing cash. Current-period financing cash use was $4,001 for a share repurchase.
Outlook, risks and other notable items
- Going concern: Management states that the company needs additional capital or profitable revenue-generating activity and that the conditions raise substantial doubt about its ability to continue as a going concern. Management says available cash is insufficient to complete its business plan and losses are expected to continue in the near term.
- Management’s plan is to raise capital and/or obtain financing, control overhead, and secure material sales or research contracts to support operations for the next twelve months and beyond. No formal financing agreements had been entered into as of the report date; success is not assured. Equity financing could dilute shareholders, while debt financing could impose restrictions.
- The company reports government-contract awards of $477,069 in the second quarter and $494,781 in the third quarter, for services and materials. The awards are firm-fixed contracts payable upon completion, with recognition expected over the next 12 months. Remaining government-contract performance obligations at March 31 were $586,350.
- The company is developing manufacturing and product capabilities, using a rapid-prototyping facility, and expects to continue engaging customers and strategic partners. It says significant expenditures will be needed before meaningful positive operating cash flow.
- Disclosure controls and procedures were assessed as not effective at March 31, 2024. Management cited insufficient finance staffing and inadequate precision, evidence, or timeliness in review controls. No material change in internal control over financial reporting was reported during the nine-month period.
- The filing reports no legal proceedings expected to have a material adverse effect and no defaults on senior securities. The company states that it is a smaller reporting company and does not provide a separate Risk Factors section in this filing.
Important facts for investors to verify
- Cash runway, financing needs, and whether new financing is obtained on acceptable terms.
- Timing and successful performance of government contracts, including conversion of remaining performance obligations into recognized revenue and cash receipts.
- Progress in commercial product sales, manufacturing readiness, and customer adoption relative to continued R&D spending.
- Remediation of the finance-staffing and review-control deficiencies, and whether disclosure controls become effective.
- Potential shareholder dilution from future equity financing and the company’s ability to meet lease and other obligations.